Q3 Sales Fall 12% but Underlying Growth Hits 21%; Margins Squeezed
STAA sits 75% above its 52-week low of $15.585.
Summary
Reported Q3 net sales of $83.4 million, down 12% year over year, but up 21% once you strip out the $25.9 million of deferred China revenue that inflated last year's quarter. China sales of $39.3 million fell 30% on the same comparison but grew 31% on the adjusted base, and management says all China-bound ICL manufacturing has now moved to Switzerland, cutting tariff exposure. The problem is profitability: gross margin dropped to 70.9% from 82.2%, operating income fell to $5.5 million from $18.5 million, and Adjusted EBITDA came in at $14.4 million versus $34.7 million a year ago. Net income was $5.6 million, or $0.11 per diluted share, against $8.9 million, or $0.18, last year. The CFO said temporary margin pressure should ease starting in Q4 as lower tariffs and smaller inventory provisions flow through, while China seasonality moderates revenue and earnings but not free cash flow. Cash and investments rose to $206.4 million from $181.5 million at the end of Q2, with no debt, and the board's $50 million buyback remains in place. First-in-human trials for two next-generation presbyopia products are expected to begin enrollment in the next few months, subject to remaining regulatory authorizations.
At the time of this announcement, STAA was trading at $27.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $15.59 to $35.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.